Regarding diacerein, Prodinger et al. reported in their review that topical diacerein regulates IL-1 activity and reduces auto-inflammatory effects on the skin of patients with Epidermolysis Bullosa Simplex (EBS). The gene discussed is IL1B; the disease is epidermolysis bullosa simplex.